Nanotechnologies in Pancreatic Cancer Therapy

Pharmaceutics

Anthony Curtis¹  Adeolu Oluwasanmi¹  Clare Hoskins¹  Ayesha Manzur¹  Darren Moss¹ 

[1] School of Pharmacy, Institute of Science and Technology for Medicine, Keele University, Keele, Staffordshire ST5 6DB, UK;

关键词: pancreatic cancer;    nanomedicine;    drug delivery;    nanoparticle;    theranostic;   

DOI  :  10.3390/pharmaceutics9040039

来源: DOAJ

【 摘 要 】

Pancreatic cancer has been classified as a cancer of unmet need. After diagnosis the patient prognosis is dismal with few surviving over 5 years. Treatment regimes are highly patient variable and often the patients are too sick to undergo surgical resection or chemotherapy. These chemotherapies are not effective often because patients are diagnosed at late stages and tumour metastasis has occurred. Nanotechnology can be used in order to formulate potent anticancer agents to improve their physicochemical properties such as poor aqueous solubility or prolong circulation times after administration resulting in improved efficacy. Studies have reported the use of nanotechnologies to improve the efficacy of gemcitabine (the current first line treatment) as well as investigating the potential of using other drug molecules which have previously shown promise but were unable to be utilised due to the inability to administer through appropriate routes—often related to solubility. Of the nanotechnologies reported, many can offer site specific targeting to the site of action as well as a plethora of other multifunctional properties such as image guidance and controlled release. This review focuses on the use of the major nanotechnologies both under pre-clinical development and those which have recently been approved for use in pancreatic cancer therapy.

【 授权许可】

Unknown